Progesterone Receptor Negative Recruiting Phase 0 Trials for Pembrolizumab (DB09037)

IndicationStatusPhase
DBCOND0038639 (Progesterone Receptor Negative)Recruiting0
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03599453Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast CancerTreatment